BioSpace News Archive

Cend Therapeutics, Inc., a clinical-stage biotech company, announced the publication of its abstract on the website of the annual meeting of the European Society for Medical Oncology.

- CRX-1008 demonstrates stabilization of TTR and normalizes TTR levels in both plasma and cerebrospinal fluid (CSF) - CRX-1008 was well tolerated with no drug related adverse events or safety concerns [15-September-2020] NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Corino Therapeutics, Inc., a private, clinical-stage pharmaceutical company, announced today that

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointments of Fitzroy Dawkins, M.D., as vice president, clinical development and Ruth du Moulin, Ph.D., as vice president, medical affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2020

Bayer has entered into an exclusive global license agreement with Systems Oncology, LLC, for ERSO™, a compound in pre-clinical development for metastatic Estrogen Receptor (ER) positive, breast cancer. ERSO is a small molecule activator of the Unfolded Protein Response (UPR) in ER-positive breast cancer cells. ERSO’s mechanism of action is a therapeutic approach being investigated in women with metastatic ER-positive bre

Cullinan Oncology, LLC, the German Cancer Research Center and the Eberhard Karls University of Tübingen, Faculty of Medicine (University of Tübingen), Germany, today announced the formation of Cullinan Florentine, a company focused on developing a novel FLT3 x CD3 bispecific antibody for the treatment of patients with acute myeloid leukemia (AML). This antibody has been developed in Tübingen wit

Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presented AbbVie to present a trial-in-progress poster of ABBV-368 in combination with tilsotolimod in recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) Idera also to present at H.C. Wainwright 22nd Annual Global Investment Conference EXTON, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA)

Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis. Abstract concludes PURE EP™ System is able to produce reliable and high-quality signals when compared to the available standard of care systems.

Enclara Pharmacia, the market leader in comprehensive pharmacy management services to the hospice community, announces the appointment of Hannah Rues as Vice President, Business Development

DLA Piper represented MEDNAX, Inc., the national health solutions partner and leading provider of maternal-fetal, newborn and pediatric subspecialty care, in the sale of MEDNAX Radiology Solutions to Radiology Partners, a leading physician-led and physician-owned radiology practice, for US$885 million.

Sept. 15, 2020 17:45 UTC Company has 89 pipeline projects spread across 6 targeted therapeutic areas with 4 programs in registration and 23 in Phase 3 27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame Pipeline contributes to the Company’s expectation of at least 6% revenue CAGR over the next five years – and delivery of longer-term topline growth beyond that period Maj